株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

中国の遺伝子組み換え型ヒトインターフェロンα2b市場の分析

Investigation Report on China's Recombinant Human Interferon Alpha 2b Market, 2018-2022

発行 China Research and Intelligence 商品コード 770554
出版日 ページ情報 英文 30 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=111.74円で換算しております。
Back to Top
中国の遺伝子組み換え型ヒトインターフェロンα2b市場の分析 Investigation Report on China's Recombinant Human Interferon Alpha 2b Market, 2018-2022
出版日: 2019年01月15日 ページ情報: 英文 30 Pages
概要

当レポートでは、中国における遺伝子組み換え型ヒトインターフェロンα2bの市場について分析し、製品の概略や背景事情、中国国内の生産高・売上高・価格の動向(過去5年間分)、企業別市場シェア、主要メーカーのプロファイル、将来的な市場動向の見通し(今後5年間分)などを調査しております。

第1章 遺伝子組み換え型ヒトインターフェロンα2bの関連概念

  • 遺伝子組み換え型ヒトインターフェロンα2bの症状
  • 中国国内での発展動向
  • 中国政府の認証状況

第2章 中国国内の遺伝子組み換え型ヒトインターフェロンα2bの売上高

  • 売上高 (過去5年間分)
    • 全体的な売上高
    • 地域別の売上高
  • 販売量 (過去5年間分)
    • 全体的な販売量
    • 地域別の販売量
  • 中国国内の販売量:投与形態別 (過去5年間分)
    • ジェル
    • 噴霧薬 (スプレー)
    • 坐薬
    • 注射薬
    • 目薬 (点眼薬)
    • カプセル
    • クリーム (軟膏)
    • 錠剤

第3章 中国の遺伝子組み換え型ヒトインターフェロンα2bの主要メーカーの分析

  • 市場シェアの分析:主要メーカー別
    • 市場シェア:売上高ベース
    • 市場シェア:販売量ベース
  • Shanghai Huaxin High Biotechnology Inc.
  • Zhaoke Pharmaceutical (Hefei) Co. Ltd.
  • Schering-Plough
  • Beijing Kawin Technology Share-Holding Co., Ltd.
  • Tianjin Sinobioway Biomedicine Co., Ltd.

第4章 中国における遺伝子組み換え型ヒトインターフェロンα2bの国内価格

  • Shanghai Huaxin High Biotechnology Inc. (Xinhuanuo)
  • Zhaoke Pharmaceutical (Hefei) Co. Ltd. (Yallaferon)
  • Schering-Plough (Intron A)
  • Beijing Kawin Technology Share-Holding Co., Ltd. (Kawin Yisheng)
  • Tianjin Sinobioway Biomedicine Co., Ltd. (Alfaron)

第5章 中国の遺伝子組み換え型ヒトインターフェロンα2b市場の将来展望

  • 市場を左右する主な要因
  • 市場規模の予測 (今後5年間分)
  • 市場動向の見通し
目次
Product Code: 1901373

Description

An interferon is a group of host-specific glycoproteins secreted by cells in response to virus infections or other factors. As a cytokine, it can defend against a wide variety of viruses by stimulating the synthesis of new effector proteins in interaction with the receptors on uninfected cells though it cannot directly kill or inhibit the viruses in cells. Besides, it can achieve immunoregulation and anti-cancer effects by enhancing the viability of lymphocytes, macrophages and natural killer cells.

In 1986, Intron A, the world's first Recombinant Human Interferon α2b, was launched by Schering Plough that was later acquired by MSD, and approved by the FDA to be used for the treatment of chronic hepatitis B. In 1997, Tianjin Sinobioway Biomedicine Co., Ltd.'s Recombinant Human Interferon α2b was approved to be sold in China, followed by the counterparts of Anhui Anke Biotechnology (Group) Co., Ltd., Zhejiang Beisheng Medicine Industry Hansheng Pharmaceutical Co., Ltd. and Schering-Plough that were approved in 1998, 1999 and 2007 respectively.

Recombinant Human Interferon α2b has been approved by the China Food and Drug Administration to be sold in the dosage forms of freeze-dried powder injection, injection, suppository, cream (ointment), eye drops, etc. The main indications include acute and chronic viral hepatitis infections (hepatitis B and hepatitis C), condyloma acuminatum, hairy cell leukemia, etc. and vary among dosage forms.

CRI estimates that by the end of 2018, more than 90 million people in China are infected with hepatitis B virus and 8 million carry hepatitis C virus. With the increasing incidence of herpes, 80%-90% of the Chinese population are infected with herpes zoster virus, and 30% of the infected may develop chickenpox, and the rest 70% will be attacked by herpes zoster when they are weak. Furthermore, over 40% of married women in China are suffering from cervical erosion.

According to CRI's market research, the sales value of Recombinant Human Interferon α2b showed an upward trend after the drug was launched in China, reaching about CNY 271 million in 2017. The injections, capsules and gels take up a large market share, with Shanghai Huaxin High Biotechnology Inc., Zhaoke Pharmaceutical (Hefei) Co. Ltd. and Schering-Plough as the top market players by sales value.

Topics Covered:

  • Status of China's Recombinant Human Interferon α2b market
  • Major manufacturers of Recombinant Human Interferon α2b in China
  • Prices of Recombinant Human Interferon α2b in China
  • Major factors influencing development of Recombinant Human Interferon α2b in China
  • Prospect of China's Recombinant Human Interferon α2b market from 2018 to 2022

Table of Contents

Table of Contents

1 Relevant Concepts of Recombinant Human Interferon α2b

  • 1.1 Indications for Recombinant Human Interferon α2b
  • 1.2 Development of Recombinant Human Interferon α2b in China
  • 1.3 Governmental Approval of Recombinant Human Interferon α2b in China

2 Sales of Recombinant Human Interferon α2b in China, 2013-2017

  • 2.1 Sales Value of Recombinant Human Interferon α2b
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Region
  • 2.2 Sales Volume of Recombinant Human Interferon α2b
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume by Region
  • 2.3 Sales of Recombinant Human Interferon α2b by Dosage Form in China, 2013-2017
    • 2.3.1 Sales of Recombinant Human Interferon α2b Gels
    • 2.3.2 Sales of Recombinant Human Interferon α2b Sprays
    • 2.3.3 Sales of Recombinant Human Interferon α2b Suppositories
    • 2.3.4 Sales of Recombinant Human Interferon α2b Injections
    • 2.3.5 Sales of Recombinant Human Interferon α2b Eye Drops
    • 2.3.6 Sales of Recombinant Human Interferon α2b Capsules
    • 2.3.7 Sales of Recombinant Human Interferon α2b Creams (Ointments)
    • 2.3.8 Sales of Recombinant Human Interferon α2b Tablets

3 Major Manufacturers of Recombinant Human Interferon α2b in China, 2013-2017

  • 3.1 Analysis on Market Share of Major Manufacturers of Recombinant Human Interferon α2b
    • 3.1.1 Market Share by Sales Value
    • 3.1.2 Market Share by Sales Volume
  • 3.2 Shanghai Huaxin High Biotechnology Inc.
  • 3.3 Zhaoke Pharmaceutical (Hefei) Co. Ltd.
  • 3.4 Schering-Plough
  • 3.5 Beijing Kawin Technology Share-Holding Co., Ltd.
  • 3.6 Tianjin Sinobioway Biomedicine Co., Ltd.

4 Prices of Recombinant Human Interferon α2b in China, 2017-2018

  • 4.1 Shanghai Huaxin High Biotechnology Inc. (Xinhuanuo)
  • 4.2 Zhaoke Pharmaceutical (Hefei) Co. Ltd. (Yallaferon)
  • 4.3 Schering-Plough (Intron A)
  • 4.4 Beijing Kawin Technology Share-Holding Co., Ltd. (Kawin Yisheng)
  • 4.5 Tianjin Sinobioway Biomedicine Co., Ltd. (Alfaron)

5 Prospect of China's Recombinant Human Interferon α2b Market, 2018-2022

  • 5.1 Major Factors Influencing Development of Recombinant Human Interferon α2b in China
  • 5.2 Forecast on Market Size of Recombinant Human Interferon α2b in China
  • 5.3 Forecast on Market Trend of Recombinant Human Interferon α2b in China

Selected Charts

  • Chart Governmental Approval of Recombinant Human Interferon α2b in China
  • Chart Sales of Recombinant Human Interferon α2b in China, 2013-2017
  • Chart Sales Value of Recombinant Human Interferon α2b in Parts of China, 2013-2017
  • Chart Sales Volume of Recombinant Human Interferon α2b in China, 2013-2017
  • Chart Sales Volume of Recombinant Human Interferon α2b in Parts of China, 2013-2017
  • Chart Sales Value of Recombinant Human Interferon α2b Gels in China, 2013-2017
  • Chart Sales Volume of Recombinant Human Interferon α2b Gels in China, 2013-2017
  • Chart Sales Value of Recombinant Human Interferon α2b Sprays in China, 2013-2017
  • Chart Sales Value of Recombinant Human Interferon α2b Suppositories in China, 2013-2017
  • Chart Sales Value of Recombinant Human Interferon α2b Injections in China, 2013-2017
  • Chart Sales Value of Recombinant Human Interferon α2b Eye Drops in China, 2013-2017
  • Chart Sales Value of Recombinant Human Interferon α2b Capsules in China, 2013-2017
  • Chart Sales Value of Recombinant Human Interferon α2b Tablets in China, 2013-2017
  • Chart Market Share by Sales Value of Top 5 Manufacturers of Recombinant Human Interferon α2b in China, 2013-2017
  • Chart Sales Value of Shanghai Huaxin High Biotechnology Inc.'s Recombinant Human Interferon α2b, 2013-2017
  • Chart Sales Volume of Shanghai Huaxin High Biotechnology Inc.'s Recombinant Human Interferon α2b, 2013-2017
  • Chart Sales Value of Zhaoke Pharmaceutical (Hefei) Co. Ltd.'s Recombinant Human Interferon α2b, 2013-2017
  • Chart Sales Value of Schering-Plough's Recombinant Human Interferon α2b, 2013-2017
  • Chart Sales Volume of Schering-Plough's Recombinant Human Interferon α2b, 2013-2017
  • Chart Sales Value of Beijing Kawin Technology Share-Holding Co., Ltd.'s Recombinant Human Interferon α2b, 2013-2017
  • Chart Prices of Shanghai Huaxin High Biotechnology Inc.'s Recombinant Human Interferon α2b (Xinhuanuo) in Parts of China, 2017-2018
  • Chart Prices of Zhaoke Pharmaceutical (Hefei) Co. Ltd.'s Recombinant Human Interferon α2b (Yallaferon) in Parts of China, 2017-2018
  • Chart Prices of Schering Plough's Recombinant Human Interferon α2b (Intron A) in Parts of China, 2017-2018
  • Chart Forecast on Sales Value of Recombinant Human Interferon α2b in China, 2018-2022
Back to Top